Urea

Urea

SCHEMBL307661

NC(=O)Nc1cccc(C(=O)O)c1.NC(N)=O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.60
MEN1 O00255 1/20 0.60
NPC1 O15118 4/20 0.58
RAB9A P51151 4/20 0.58
HPSE Q9Y251 1/20 0.57
CBS P35520 1/20 0.55
MITF O75030 2/20 0.54
CASR P41180 1/20 0.54
PKM P14618 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
LMNA P02545 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
MAPK1 P28482 1/20 0.53
NR1H4 Q96RI1 1/20 0.53
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
GFER P55789 1/20 0.52
KCNK3 O14649 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5210059 0.98 KMT2A (0.62) KMT2AMEN1NPC1RAB9AHPSE
SCHEMBL2850002 0.85 MEN1 (0.67) KMT2AMEN1
SCHEMBL1185244 0.84 KMT2A (0.58) KMT2AMEN1NPC1RAB9AHPSE
SCHEMBL687614 0.84 ALDH1A1 (0.69) KMT2AMEN1NPC1RAB9AHPSE
SCHEMBL11015498 0.84 L3MBTL1 (0.64) KMT2AMEN1RAB9AL3MBTL1LMNA
SCHEMBL4795890 0.83 KMT2A (0.66) KMT2AMEN1NPC1RAB9ALMNA
SCHEMBL23932088 0.82 KMT2A (0.66) KMT2AMEN1NPC1RAB9AHPSE
SCHEMBL4749812 0.82 NPC1 (0.80) KMT2AMEN1NPC1RAB9AHPSE
Hydrochloric Acid SCHEMBL29568124 0.82 KMT2A (0.57) KMT2AMEN1NPC1RAB9AHPSE
Hydrochloric Acid SCHEMBL3839558 0.82 KMT2A (0.57) KMT2AMEN1NPC1RAB9AHPSE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114869-B1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-07-23 EP disclosed
US-8093266-B2 Rho kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-10 US disclosed
US-20100041645-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 US disclosed
EP-2114869-A1 RHO KINASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2009-11-11 EP disclosed
WO-2008086047-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041645-A1 RHO KINASE INHIBITORS CIT, ROCK1, RHOT2 KMT2A 2067/4885MEN1 1736/4885NPC1 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.